Sonoma Pharmaceuticals Inc(SNOA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 24 at 7:24 PM ET (Korea 9/25 08:24)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.22 | Insider Own | 0.44% | Shs Outstand | 4.8M | Perf Week | -1.19% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.8M | Perf Month | -7.78% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 2.31% | Short Float | 4.22% | Perf Quarter | 9.21% |
| Income | -0.00B | P/S | 0.27 | EPS this Y | - | Inst Trans | 1.06% | Short Ratio | 1.57 | Perf Half Y | -45.39% |
| Sales | 0.02B | P/B | 0.9 | EPS next 5Y | - | ROA | -13.85% | Short Interest | 0.20M | Perf YTD | -65.8% |
| Book/sh | 1.38 | P/C | 1.12 | EPS past 3/5Y | 60.4% 47.5% | ROE | -42.52% | 52W High | -72.93% ($4.60) | Perf Year | -69.49% |
| Cash/sh | 1.11 | P/FCF | - | Sales past 3/5Y | 13.74% 0.95% | ROIC | -32.19% | 52W Low | 46.45% ($0.85) | Perf 3Y | -92.02% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 50.49% | Gross Margin | 38.91% | Volatility(W/M) | 5.18% 3.88% | Perf 5Y | -98.84% |
| Dividend TTM | - | EV/Sales | 0.06 | Sales Y/Y TTM | 47% | Oper. Margin | -6.41% | ATR (14) | 0.06 | Perf 10Y | -99.83% |
| Dividend Ex-Date | - | Quick Ratio | 2.29 | EPS Q/Q | 88.65% | Profit Margin | -10.33% | RSI (14) | 44.64 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.99 | Sales Q/Q | 59.55% | SMA20 | -3.41% ($1.29) | Beta | 1.31 | Target Price | $12 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/8/6 | SMA50 | -1.5% ($1.27) | Rel Volume | 0.61 | Prev Close | $1.25 |
| Employees | 259 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | - | SMA200 | -38.28% ($2.03) | Avg Volume(3M) | 0.13M | Price | $1.25 |
| IPO | 2007/1/25 | Option/Short | No/Yes | Trades | 232 | Volume | 78,486 | Change | -0.4% |
Company
SNOA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A pharmaceutical company specializing in dermatology products. Wound and skin treatment products based on hypochlorous acid (HOCl). Holds patents for Q-Mycin technology. Currently expanding globally.
Over the past 1 year, on the lower side
73% below its 1-year high.
SNOA has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -92.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 2.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VXF 0.00%It ranks #4 in the industry
Based on market cap of $6M.
SNOA $6M PER -
TAK $59B PER -
TEVA $47B PER 67.1
HLN $41B PER 19.0
FAQ
What kind of company is SNOA?
SNOA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SNOA?
The market cap of SNOA is approximately $6M, ranking 5,643 within its sector.
What is the 52-week high and low for SNOA?
SNOA has recorded a 52-week high of $4.60 and a low of $0.85.
